Ashvattha Therapeutics to Present Preclinical Data at CMSC and SNMMI Meetings
Ashvattha Therapeutics has unveiled promising preclinical data showcasing the therapeutic efficacy of its innovative CSF1R tyrosine kinase inhibitor, known as CSF1R dendranib, in tackling multiple sclerosis (MS). Utilizing Ashvattha's proprietary hydroxyl dendrimer nanomedicine technology, the orally bioavailable CSF1R dendranib (H74DS3M8) has been specifically designed to circumvent the safety issues associated with other CSF1R inhibitors.
The preclinical findings, set to be presented at the Consortium of Multiple Sclerosis Centers (CMSC) and the Society of Nuclear Medicine & Molecular Imaging 2024 annual meetings, highlight significant symptom reduction in the EAE mouse model of MS. These results are attributed to the reduction in neuroinflammation achieved through the administration of CSF1R dendranib, as demonstrated by collaborative studies conducted at Stanford University. The studies utilized Ashvattha’s 18F-OP-801 PET imaging agent to observe this neuroinflammation reduction.
Ashvattha Therapeutics, a clinical-stage company, is pioneering a new class of nanomedicine therapeutics. These therapeutics are designed to traverse tissue barriers and selectively target activated cells in inflamed regions, potentially revolutionizing treatment approaches in ophthalmology, neurology, and other inflammation-related conditions.
The details of the presentations are as follows:
1. CMSC Annual Meeting 2024
- Dates: May 29 – June 1, 2024
- Location: Music City Center, Nashville, TN
- Poster Title: A Novel ‘Dendranib’ Inhibiting CSF1R Tyrosine Kinase (H74DS3M8) is an Immunomodulatory and Anti-Inflammatory Agent that Attenuates EAE and Promotes Disease Improvement
- Poster Board Label: DMT41
- Presenter: S. Sakura Minami, Ph.D., Ashvattha Therapeutics
- Presentation Time: Thursday, May 30, 2024, 5:00-7:00 p.m. CT
2. SNMMI Annual Meeting 2024
- Dates: June 8-11, 2024
- Location: Metro Toronto Convention Center, Toronto, ON, Canada
- Presentation Title: Early detection and tracking of activated macrophages and microglia in a mouse model of multiple sclerosis using 18F-OP-801 PET imaging before and after a novel immunomodulatory drug
- Session Title: Brain Imaging Council Young Investigator Award
- Presenter: Renesmee C. Kuo from Michelle James Lab at Stanford University
- Presentation Time: Saturday, June 8, 2024, 2:05-2.15 p.m. ET
The preclinical data suggests that CSF1R dendranib could provide significant therapeutic benefits in the treatment of MS by effectively reducing neuroinflammation. This positions Ashvattha’s nanomedicine approach as a promising solution to unmet needs in precision medicine, potentially setting a new standard in the management of inflammatory conditions.
Ashvattha Therapeutics continues to advance its targeted nanomedicine approach, promising to deliver more effective treatments by focusing on precision targeting of inflamed cells, thus minimizing potential side effects and enhancing therapeutic outcomes.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
